KCNJ11
ENSG00000187486
Target class
Ion channel
Chromosome
11
Approved drugs
13
Clinical candidates (approved and in development)
18
- Approved drugs
- 13
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 18
- Chemical probe available
- Yes
- Target name
- KCNJ11
- Gene name
- Potassium inwardly rectifying channel subfamily J member 11
- Gene symbol
- KCNJ11
- Protein name
- ATP-sensitive inward rectifier potassium channel 11 (IKATP) (Inward rectifier K(+) channel Kir6.2) (Potassium channel, inwardly rectifying subfamily J member 11)
- Kir6.2
- BIR
- Gene biotype
- Protein coding
- Gene family
- Potassium inwardly rectifying channel subfamily J
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 40
- Highest tissue expression
- 87.08
- Tissue specificity (Gini)
- 0.696
- Tissue specificity (tau)
- 0.947
- KEGG gene identifiers
- hsa:3767
- Protein interaction confidence
- 0.808971
- Protein interaction partners
- 34
- R-HSA-1296025
- R-HSA-382556
- R-HSA-422356
- R-HSA-5578775
- R-HSA-5678420
- R-HSA-5683177
- End position
- 17389353
- Start position
- 17365172
- Chromosome
- 11
- Strand
- Reverse
- Membrane
- Multi-pass membrane protein.
- Tissue specificity (tau)
- 0.947301
- Expression inequality (Gini)
- 0.695846
Expression in transcripts per million
- Muscle - Skeletal
- 87.08
- Brain - Cerebellum
- 37.37
- Brain - Cerebellar Hemisphere
- 36.79
- Brain - Cortex
- 13.99
- Brain - Frontal Cortex (BA9)
- 13.9
Expression in transcripts per million
- Muscle - Skeletal87.08
- Brain - Cerebellum37.37
- Brain - Cerebellar Hemisphere36.79
- Brain - Cortex13.99
- Brain - Frontal Cortex (BA9)13.9
- Stomach12.19
- Pituitary10.73
- Thyroid8.52
- Heart - Atrial Appendage7.87
- Brain - Caudate (basal ganglia)7.6
- Heart - Left Ventricle7.41
- Brain - Anterior cingulate cortex (BA24)7.3
- Pancreas6.13
- Brain - Nucleus accumbens (basal ganglia)6.03
- Brain - Putamen (basal ganglia)5.62
- Brain - Hypothalamus4.18
- Breast - Mammary Tissue3.99
- Brain - Hippocampus3.75
- Kidney - Medulla3.52
- Brain - Amygdala3.51
- Nerve - Tibial3.28
- Brain - Substantia nigra3.21
- Lung2.69
- Prostate2.62
- Brain - Spinal cord (cervical c-1)2.59
And 29 more, listed on the interactive page.
- GO:0006006
- GO:0009410
- GO:0033198
- GO:0042391
- GO:0046676
- GO:0050796
- GO:0050877
- GO:1990573
- GO:0005886
- GO:0008282
- GO:0005249
- GO:0005515
- GO:0030506
- GO:0030955
- GO:0044325
- GO:0099508
abnormal pulse
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: abnormal pulse
- pancreas
- renal
- cardiovascular
PubMed 28216264increased/decreased blood glucose
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased/decreased blood glucose
- pancreas
- renal
- cardiovascular
PubMed 28216264increased urinary sodium excretion
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased urinary sodium excretion
- pancreas
- renal
- cardiovascular
PubMed 28216264decreased blood pressure
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased blood pressure
- pancreas
- renal
- cardiovascular
PubMed 28216264decreased heart rate
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased heart rate
- pancreas
- renal
- cardiovascular
PubMed 28216264decreased blood glucose
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased blood glucose
- pancreas
- renal
- cardiovascular
PubMed 28216264cardiac lesions
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: cardiac lesions
- pancreas
- renal
- cardiovascular
PubMed 28216264increased heart rate
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased heart rate
- pancreas
- renal
- cardiovascular
PubMed 28216264cardiac arrhythmia
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: cardiac arrhythmia
- pancreas
- renal
- cardiovascular
PubMed 28216264atrioventricular block
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: atrioventricular block
- pancreas
- renal
- cardiovascular
PubMed 28216264decreased blood insulin
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased blood insulin
- pancreas
- renal
- cardiovascular
PubMed 28216264decreased convulsions
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased convulsions
- pancreas
- renal
- cardiovascular
PubMed 28216264increased blood insulin
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased blood insulin
- pancreas
- renal
- cardiovascular
PubMed 28216264increased urine excretion
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased urine excretion
- pancreas
- renal
- cardiovascular
PubMed 28216264
Related records
Trials (817)
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)
- A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone
- A Bioequivalence Study of Glibenclamide From Glibesyn 5 mg Tablets (Medochemie LTD Cyprus) and Daonil 5 mg Tablets (Sanofi-Aventis Cyprus Ltd. )
- A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone
- A Clinical Observation of 1565nm Non-ablative Fractional Laser in the Treatment of Androgenic Alopecia
- A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes
- A Comparison Between Two Oral Hypoglycemics - Metformin and Glybenclamide for the Treatment of Gestational Diabetes Mellitus
- A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus
- A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)
- A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of an Antidiabetic Agent Repaglinide for the Treatment of Type 2 Diabetes Mellitus Patients
- A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects
- A Drug Interaction Study of LY3871801 in Healthy Participants
- A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or Lymphoma
- A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.
- A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants
- A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants
- A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib
- A Drug-Drug Interaction Study of GK Activator (2) and Glyburide in Patients With Type 2 Diabetes.
- A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST
Drugs (19)
- Acetohexamide Sulfonylurea receptor 1, Kir6.2 blocker
- Chlorpropamide Sulfonylurea receptor 1, Kir6.2 blocker
- Diazoxide Potassium channel, inwardly rectifying, subfamily J, member 11 opener
- Gliclazide Sulfonylurea receptor 1, Kir6.2 blocker
- Glimepiride Sulfonylurea receptor 1, Kir6.2 blocker
- Glipizide Sulfonylurea receptor 1, Kir6.2 blocker
- Glyburide Sulfonylurea receptor 1, Kir6.2 blocker
- Minoxidil Sulfonylurea receptor 2, Kir6.2 opener
- Mitiglinide Sulfonylurea receptor 1, Kir6.2 blocker
- Mitiglinide calcium dihydrate Sulfonylurea receptor 1, Kir6.2 blocker
- Naminidil Sulfonylurea receptors; K-ATP channels opener
- Nateglinide Sulfonylurea receptor 1, Kir6.2 blocker
- Pinacidil Sulfonylurea receptor 2, Kir6.2 opener
- Pinacidil anhydrous Sulfonylurea receptor 2, Kir6.2 opener
- Repaglinide Sulfonylurea receptor 1, Kir6.2 blocker
- Sarakalim Sulfonylurea receptors; K-ATP channels opener
- Tolazamide Sulfonylurea receptor 1, Kir6.2 blocker
- Tolbutamide Sulfonylurea receptor 1, Kir6.2 blocker
- Tolbutamide sodium Sulfonylurea receptor 1, Kir6.2 blocker